Captopril is indicated for the treatment congestive heart failure and hypertension. Captopril is an oral antihypertensive agent that blocks the conversion of angiotensin I to angiotensin II by inhibiting angiotensin I-converting enzyme (ACE), a peptidyldipeptide carboxy hydrolase. It exerts its effect in hypertension and heart failure by suppressing the renin-angiotensin system. Collectively, the pharmacologic effects of ACE inhibition result in a decrease in systemic vascular resistance, reducing blood pressure, preload, and afterload. Reductions in blood pressure are not accompanied by changes in heart rate, pressor sensitivity to exogenous norepinephrine or baroreceptor sensitivity.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.